MetLife Investment Management LLC raised its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 89,418 shares of the life sciences company's stock after acquiring an additional 7,083 shares during the quarter. MetLife Investment Management LLC owned approximately 0.06% of Illumina worth $11,949,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Golden State Wealth Management LLC acquired a new position in Illumina in the 4th quarter valued at $32,000. Versant Capital Management Inc raised its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina during the fourth quarter worth about $45,000. Assetmark Inc. grew its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after buying an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in Illumina in the 4th quarter valued at about $48,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
ILMN has been the topic of a number of recent analyst reports. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Citigroup decreased their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Guggenheim lowered their target price on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Morgan Stanley decreased their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $138.70.
Check Out Our Latest Stock Report on ILMN
Illumina Stock Performance
Shares of NASDAQ ILMN traded up $1.90 during trading on Wednesday, reaching $76.25. 1,661,007 shares of the company traded hands, compared to its average volume of 2,276,444. The stock has a market cap of $12.07 billion, a P/E ratio of -9.93, a PEG ratio of 1.60 and a beta of 1.38. The firm's fifty day simple moving average is $82.95 and its 200 day simple moving average is $119.06. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
Illumina Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
